Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Checkpoint Inhibitors | Research

Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer

Authors: Hao Jiang, Borui Li, Min Wu, Qimei Wang, Yijin Li

Published in: BMC Cancer | Issue 1/2024

Abstract

Objective

This study aimed to conduct a comprehensive analysis, evaluating the prognostic significance of the baseline Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) Score in patients undergoing immune checkpoint inhibitor (ICI) therapy.

Methods

A comprehensive search was performed across various databases, including PubMed, the Cochrane Library, EMBASE, and Google Scholar, until October 21, 2023, to compile relevant articles for analysis. The investigation encompassed diverse clinical outcomes, including overall survival (OS) and progression-free survival (PFS).

Results

This analysis included a total of 15 articles, comprising 19 studies involving 3335 patients. Among the 19 studies, nine studies focused on NSCLC, and six studies were conducted on HCC. Pooled results revealed that patients with elevated ALI levels experienced prolonged OS (HR: 0.51, 95% CI: 0.37–0.70, p < 0.001) and extended PFS (HR: 0.61, 95% CI: 0.52–0.72, p < 0.001). Furthermore, a GRIm score > 1 was associated with reduced OS (HR: 2.07, 95% CI: 1.47–2.92, p < 0.001) and diminished PFS (HR: 1.78, 95% CI: 1.35–2.34, p < 0.001) in cancer patients receiving ICIs. Subgroup analysis indicated that ALI cutoff values of 18 exhibited enhanced predictive potential. Additionally, for HCC patients, those with HCC-GRIm score > 2 showed a substantially decreased risk of mortality compared to individuals with HCC-GRIm score ≤ 2 (HR: 2.63, 95% CI: 1.89–3.65, p < 0.001).

Conclusion

The ALI and GRIm score served as dependable prognostic indicators for patients undergoing ICI therapy in the context of cancer treatment.

Available only for authorised users

Zhao J, Li D, Xie S, Deng X, Wen X, Li J, Wu Z, Yang X, Li M, Tang Y, et al. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: a Chinese population-based analysis. Front Immunol. 2022;13:1083840.PubMedPubMedCentralCrossRef

Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.PubMedPubMedCentralCrossRef

Liu LL, Skribek M, Harmenberg U, Gerling M. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. J Immunother Cancer 2023, 11(3).

Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023;72(6):1365–79.PubMedCrossRef

Zhang L, Kuang T, Chai D, Deng W, Wang P, Wang W. The Use of Antibiotics during Immune checkpoint inhibitor treatment is Associated with Lower Survival in Advanced Esophagogastric Cancer. Int Immunopharmacol. 2023;119:110200.PubMedCrossRef

Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, et al. Long-term survival in patients responding to Anti-PD-1/PD-L1 therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2019;25(3):946–56.PubMedCrossRef

Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, et al. Immune checkpoint inhibitor Rechallenge after Immune-related adverse events in patients with Cancer. JAMA Oncol. 2020;6(6):865–71.PubMedCrossRef

Zhang L, Feng J, Kuang T, Chai D, Qiu Z, Deng W, Dong K, Zhao K, Wang W. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors: a pooled analysis of 44 retrospective sudies. Int Immunopharmacol. 2023;118:110019.PubMedCrossRef

Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N, Massari F. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596.PubMedCrossRef

10.

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Montagna ES, Ungaro V, Lorusso M, Palmiotti G. Impact of Proton Pump inhibitors and histamine-2-Receptor antagonists on Non-small Cell Lung Cancer Immunotherapy: a systematic review and Meta-analysis. Cancers (Basel) 2022, 14(6).

11.

Ren J, Wang A, Liu J, Yuan Q. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma. Bioengineered. 2021;12(1):4331–48.PubMedPubMedCentralCrossRef

12.

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50.PubMedPubMedCentralCrossRef

13.

Qu FJ, Zhou Y, Wu S. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases. Br J Cancer. 2024;130(2):165–75.PubMedCrossRef

14.

Steen S, Semmelmayer K, Flechtenmacher C, Hoffmann J, Freier K, Horn D, Hess J, Freudlsperger C, Moratin J. Dynamic Up-Regulation of PD-L1 in the progression of oral squamous cell carcinoma. Int J Mol Sci 2023, 24(22).

15.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef

16.

Guven DC, Sahin TK, Erul E, Rizzo A, Ricci AD, Aksoy S, Yalcin S. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Mol Biosci. 2022;9:1039121.PubMedPubMedCentralCrossRef

17.

Wang YT, Fang KH, Hsu CM, Chang GH, Lai CH, Lee YC, Tsai MS, Huang EI, Tsai YT. Retrospective study on the potential of albumin/globulin ratio as a prognostic biomarker for oral cavity cancer patients. Eur Arch Otorhinolaryngol. 2021;278(1):227–38.PubMedCrossRef

18.

Yang L, Huang Y, Zhou L, Dai Y, Hu G. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: systematic review and meta-analysis. Head Neck. 2019;41(5):1525–35.PubMedCrossRef

19.

Minami S, Ihara S, Ikuta S, Komuta K. Gustave Roussy Immune score and Royal Marsden Hospital Prognostic Score are biomarkers of Immune-Checkpoint inhibitor for Non-small Cell Lung Cancer. World J Oncol. 2019;10(2):90–100.PubMedPubMedCentralCrossRef

20.

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune score (GRIm-Score). Eur J Cancer. 2017;84:212–8.PubMedCrossRef

21.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-small-cell Lung Cancer. N Engl J Med. 2018;378(22):2078–92.PubMedCrossRef

22.

Li Y, Pan Y, Lin X, Hou J, Hu Z, Xu L, Zhou Z, Zhang Y, Chen M, Hu D. Development and validation of a Prognostic score for Hepatocellular Carcinoma patients in Immune checkpoint inhibitors therapies: the Hepatocellular Carcinoma Modified Gustave Roussy Immune score. Front Pharmacol. 2021;12:819985.PubMedCrossRef

23.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.PubMedPubMedCentralCrossRef

24.

Zhang L, Ma W, Qiu Z, Kuang T, Wang K, Hu B, Wang W. Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors. Front Immunol. 2023;14:1219929.PubMedPubMedCentralCrossRef

25.

Zhang L, Chen C, Chai D, Li C, Guan Y, Liu L, Kuang T, Deng W, Wang W. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Front Immunol. 2022;13:956533.PubMedPubMedCentralCrossRef

26.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedPubMedCentralCrossRef

27.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef

28.

Zhang L, Yuan Q, Li M, Chai D, Deng W, Wang W. The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis. BMC Cancer. 2020;20(1):1167.PubMedPubMedCentralCrossRef

29.

Li Q, Ma F, Wang JF. Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy. Front Oncol. 2023;13:997314.PubMedPubMedCentralCrossRef

30.

Hatanaka T, Naganuma A, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, et al. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: a multicenter retrospective analysis. Cancer Med. 2023;12(4):4259–69.PubMedCrossRef

31.

Nakazawa N, Sohda M, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, et al. Changes in the Gustave Roussy Immune score as a powerful prognostic marker of the therapeutic sensitivity of Nivolumab in Advanced Gastric Cancer: a Multicenter, Retrospective Study. Ann Surg Oncol. 2022;29(12):7400–6.PubMedCrossRef

32.

Minichsdorfer C, Gleiss A, Aretin MB, Schmidinger M, Fuereder T. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Ann Med. 2022;54(1):1339–49.PubMedPubMedCentralCrossRef

33.

Holtzman L, Moskovitz M, Urban D, Nechushtan H, Keren S, Reinhorn D, Wollner M, Daher S, Rottenberg Y, Rovitzky Y, et al. dNLR-Based score Predicting overall survival benefit for the addition of platinum-based chemotherapy to Pembrolizumab in Advanced NSCLC with PD-L1 tumor proportion score ≥ 50%. Clin Lung Cancer. 2022;23(2):122–34.PubMedCrossRef

34.

Qi WX, Xiang Y, Zhao S, Chen J. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother. 2021;70(11):3199–206.PubMedCrossRef

35.

Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open. 2021;6(5):100254.PubMedPubMedCentralCrossRef

36.

Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S et al. The Gustave Roussy Immune (GRIm)-Score variation is an early-on-treatment biomarker of Outcome in Advanced Non-small Cell Lung Cancer (NSCLC) patients treated with First-Line Pembrolizumab. J Clin Med 2021, 10(5).

37.

Al Darazi G, Martin E, Delord JP, Korakis I, Betrian S, Estrabaut M, Poublanc M, Gomez-Roca C, Filleron T. Improving patient selection for immuno-oncology phase 1 trials: external validation of six prognostic scores in a French Cancer Center. Int J Cancer 2020.

38.

Adachi Y, Tamiya A, Taniguchi Y, Enomoto T, Azuma K, Kouno S, Inagaki Y, Saijo N, Okishio K, Atagi S. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. Cancer Med. 2020;9(4):1383–91.PubMedCrossRef

39.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med. 2018;7(1):13–20.PubMedCrossRef

40.

Yamaguchi O, Kaira K, Imai H, Mouri A, Shiono A, Miura Y, Hashimoto K, Kobayashi K, Kagamu H. Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC. Oncology 2023.

41.

Liu C, Zhao H, Zhang R, Guo Z, Wang P, Qu Z. Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors. Oncol Lett. 2023;26(4):437.PubMedPubMedCentralCrossRef

42.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006–12.PubMedCrossRef

43.

Yuan Q, Zhang W, Shang W. Identification and validation of a prognostic risk-scoring model based on sphingolipid metabolism-associated cluster in colon adenocarcinoma. Front Endocrinol (Lausanne). 2022;13:1045167.PubMedCrossRef

44.

Zhang B, Sun J, Guan H, Guo H, Huang B, Chen X, Chen F, Yuan Q. Integrated single-cell and bulk RNA sequencing revealed the molecular characteristics and prognostic roles of neutrophils in pancreatic cancer. Aging 2023, 15.

45.

Hasegawa T, Yanagitani N, Utsumi H, Wakui H, Sakamoto H, Tozuka T, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, et al. Association of High Neutrophil-to-Lymphocyte Ratio with Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing non-small cell Lung Cancer. Anticancer Res. 2019;39(12):6851–7.PubMedCrossRef

46.

Zhu GL, Yang KB, Tang SQ, Peng L. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: a systematic review and meta-analysis. Cancer Med. 2021;10(23):8272–87.PubMedPubMedCentralCrossRef

47.

Zhao Y, Wei K, Chi H, Xia Z, Li X. IL-7: a promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines? Front Immunol. 2022;13:1022808.PubMedPubMedCentralCrossRef

48.

Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503.PubMedCrossRef

49.

Wang Z, Yuan Q, Chen X, Luo F, Shi X, Guo F, Ren J, Li S, Shang D. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo. Funct Integr Genomics. 2023;23(3):263.PubMedPubMedCentralCrossRef

50.

Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018;11:955–65.PubMedPubMedCentralCrossRef

51.

Yuan Q, Deng D, Pan C, Ren J, Wei T, Wu Z, Zhang B, Li S, Yin P, Shang D. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy. Front Immunol. 2022;13:951137.PubMedPubMedCentralCrossRef

52.

Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019;452:66–70.PubMedCrossRef

53.

Banna GL, Signorelli D, Metro G, Galetta D, De Toma A, Cantale O, Banini M, Friedlaender A, Pizzutillo P, Garassino MC, et al. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Transl Lung Cancer Res. 2020;9(4):1533–42.PubMedPubMedCentralCrossRef

54.

Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, et al. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with Nivolumab in Pretreated Non-small Cell Lung Cancer (NSCLC): a large Retrospective Multicenter Study. Adv Ther. 2020;37(3):1145–55.PubMedCrossRef

55.

Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74.PubMedPubMedCentralCrossRef

56.

Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56(6):782–9.PubMedCrossRef

57.

Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014;89(1):129–39.PubMedCrossRef

58.

Ock CY, Nam AR, Lee J, Bang JH, Lee KH, Han SW, Kim TY, Im SA, Kim TY, Bang YJ, et al. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer. 2017;20(2):254–62.PubMedCrossRef

59.

Ding P, Wu J, Wu H, Sun C, Guo H, Lowe S, Yang P, Tian Y, Liu Y, Meng L, et al. Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib. BMC Gastroenterol. 2023;23(1):23.PubMedPubMedCentralCrossRef

60.

Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58–64.PubMedCrossRef

61.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.PubMedCrossRef

62.

Evans DC, Corkins MR, Malone A, Miller S, Mogensen KM, Guenter P, Jensen GL. The Use of visceral proteins as Nutrition markers: an ASPEN position paper. Nutr Clin Pract. 2021;36(1):22–8.PubMedCrossRef

63.

Ding P, Lv J, Sun C, Chen S, Yang P, Tian Y, Zhou Q, Guo H, Liu Y, Zhao Q. Combined systemic inflammatory immunity index and prognostic nutritional index scores as a screening marker for Sarcopenia in patients with locally advanced gastric cancer. Front Nutr. 2022;9:981533.PubMedPubMedCentralCrossRef

64.

Xiong J, Chi H, Yang G, Zhao S, Zhang J, Tran LJ, Xia Z, Yang F, Tian G. Revolutionizing anti-tumor therapy: unleashing the potential of B cell-derived exosomes. Front Immunol. 2023;14:1188760.PubMedPubMedCentralCrossRef

65.

Coffelt SB, de Visser KE. Cancer: inflammation lights the way to metastasis. Nature. 2014;507(7490):48–9.PubMedCrossRef

66.

Bito R, Hino S, Baba A, Tanaka M, Watabe H, Kawabata H. Degradation of oxidative stress-induced denatured albumin in rat liver endothelial cells. Am J Physiol Cell Physiol. 2005;289(3):C531–542.PubMedCrossRef

67.

Aday U, Tatlı F, Akpulat FV, İnan M, Kafadar MT, Bilge H, Başol Ö, Oğuz A. Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer. Contemp Oncol (Pozn). 2020;24(3):145–9.PubMed

68.

Taniguchi Y, Tamiya A, Isa SI, Nakahama K, Okishio K, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, et al. Predictive factors for poor progression-free survival in patients with non-small cell Lung Cancer treated with Nivolumab. Anticancer Res. 2017;37(10):5857–62.PubMed

69.

Agulló-Ortuño MT, Gómez-Martín Ó, Ponce S, Iglesias L, Ojeda L, Ferrer I, García-Ruiz I, Paz-Ares L. Pardo-Marqués V: blood predictive biomarkers for patients with non-small-cell Lung Cancer Associated with Clinical Response to Nivolumab. Clin Lung Cancer. 2020;21(1):75–85.PubMedCrossRef

70.

Kang BW, Chau I. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. ESMO Open 2020, 5(4).

Title: Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer
Authors: Hao Jiang
Borui Li
Min Wu
Qimei Wang
Yijin Li
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Checkpoint Inhibitors
Lung Cancer
Lung Cancer
Lung Cancer
Hepatocellular Carcinoma
Hepatocellular Carcinoma
NSCLC
NSCLC
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12149-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma

Prediction of the Ki-67 expression level in head and neck squamous cell carcinoma with machine learning-based multiparametric MRI radiomics: a multicenter study

The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells

LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism

A chest CT-based nomogram for predicting survival in acute myeloid leukemia

Neuroendocrine carcinoma of the endometrium: a retrospective analysis of data from a single center

Keynote webinar | Spotlight on antibody–drug conjugates in cancer